Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
Not yet recruiting · NCT07325201 · Registry updated 2026-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring. | Acid-Base Imbalance, Chronic Disease, Diabetes Complications, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Ketosis, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, acidosis disorder, autoimmune disease, chronic renal failure syndrome, diabetes mellitus, diabetic ketoacidosis, endocrine system disorder, glucose metabolism disease, immune system disorder, kidney disorder, kidney failure, metabolic disease, type 1 diabetes mellitus, urinary system disorder | Not yet recruiting | Phase 2 | 2026-08-27 | NCT07325201 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| HealthPartners Institute | 29 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 617 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| International Diabetes Center | Minneapolis | United States | 8 |